Method for utilizing engineered dendritic cells to induce gut-homing regulatory T cells and treat gut inflammation
US10577669B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Feb 11, 2016 |
| Grant date | Mar 3, 2020 |
| Priority date | — |
| Expiry date | Feb 11, 2036 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2239/38
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Gene-modified, lymphoid-tissue-homing dendritic cells that comprise a 1-alpha-hydroxylase gene and a retinaldehyde dehydrogenase 2 gene, where the 1-alpha-hydroxylase gene is expressed to produce functional 1-alpha-hydroxylase enzyme and the retinaldehyde dehydrogenase 2 gene is expressed to produce functional retinaldehyde dehydrogenase 2 gene enzyme. A method for treating one or more than one inflammation-related condition or disease, the method comprising administering gene-modified, lymphoid-tissue-homing dendritic cells that comprise a 1-alpha-hydroxylase gene and a retinaldehyde dehydrogenase 2 gene, where the 1-alpha-hydroxylase gene is expressed to produce functional 1-alpha-hydroxylase enzyme and the retinaldehyde dehydrogenase 2 gene is expressed to produce functional retinaldehyde dehydrogenase 2 gene enzyme.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.